- Home
- CRML vs TIL Comparison
CRML vs TIL Comparison
Compare CRML & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRML
- TIL
- Stock Information
- Founded
- CRML N/A
- TIL 2018
- Country
- CRML United States
- TIL United States
- Employees
- CRML N/A
- TIL N/A
- Industry
- CRML
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- CRML
- TIL Health Care
- Exchange
- CRML NYSE
- TIL Nasdaq
- Market Cap
- CRML 177.5M
- TIL 171.7M
- IPO Year
- CRML N/A
- TIL 2021
- Fundamental
- Price
- CRML $1.42
- TIL $29.65
- Analyst Decision
- CRML
- TIL Buy
- Analyst Count
- CRML 0
- TIL 5
- Target Price
- CRML N/A
- TIL $119.00
- AVG Volume (30 Days)
- CRML 2.1M
- TIL 359.9K
- Earning Date
- CRML 02-01-2025
- TIL 05-13-2025
- Dividend Yield
- CRML N/A
- TIL N/A
- EPS Growth
- CRML N/A
- TIL N/A
- EPS
- CRML N/A
- TIL N/A
- Revenue
- CRML $476,979.00
- TIL N/A
- Revenue This Year
- CRML N/A
- TIL N/A
- Revenue Next Year
- CRML N/A
- TIL N/A
- P/E Ratio
- CRML N/A
- TIL N/A
- Revenue Growth
- CRML 326.80
- TIL N/A
- 52 Week Low
- CRML $1.23
- TIL $9.62
- 52 Week High
- CRML $12.00
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- CRML 43.59
- TIL 68.29
- Support Level
- CRML $1.33
- TIL $23.47
- Resistance Level
- CRML $1.64
- TIL $35.28
- Average True Range (ATR)
- CRML 0.13
- TIL 4.40
- MACD
- CRML 0.01
- TIL 1.58
- Stochastic Oscillator
- CRML 36.96
- TIL 66.50
About CRML CRITICAL METALS CORPORATION
Critical Metals Corp is engaged in lithium exploration in Austria. It is focused on the development of its wholly-owned Wolfsberg Lithium Project (the Wolfsberg Project) located in Carinthia, Austria.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.